Asia Beat: Some rays of light in a gloomy world
This article was originally published in Scrip
Despite the patent expiration and R&D woes facing the global industry, it's hard not to feel a little positive about some of the trends emerging so far in 2011, at least in this part of the world.
You may also be interested in...
While it has raised the full-year profit outlook, Takeda came in under analysts' consensus for some of its fiscal first-half figures, pointing to a growing forex impact.
Product review report reveals multiple delays and missteps on route to market, holding valuable lessons for other gene therapy developers but also evidencing an ultimately welcoming environment.
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.